199
Participants
Start Date
March 27, 2015
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Etripamil
intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Placebo
intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Medstar Washington Hospital Center, Washington D.C.
MedStar Health Research Institute, Baltimore
University of Virginia Medical Center, Charlottesville
Sentara Norfolk General Hospital, Norfolk
Centra Stroobants Cardiovascular Center, Lynchburg
Piedmont Atlanta Hospital, Atlanta
Emory University Hospital, Atlanta
Memorial Hospital Jacksonville, Jacksonville
Mayo Clinic Jacksonville, Jacksonville
University of South Florida Health South Tampa Center, Tampa
Northside Hospital, St. Petersburg
ProMedica Toledo Hospital, Toledo
Great Lakes Medical Research, LLC, Willoughby
Aultman Hospital Cardiology Clinical Trials, Canton
University of Cincinnati Medical Center Division of Cardiovascular Diseases, Cincinnati
Iowa Heart Center, West Des Moines
Mayo Clinic, Rochester
Black Hills Cardiovascular Research, Rapid City
University of Kansas Medical Center, Kansas City
Baylor St. Luke's Hospital, Houston
Houston Methodist Hospital, Houston
Texas Cardiac Arrhythmia Research Foundation, Austin
South Denver Cardiology Associates, Littleton
Arizona Heart Rhythm Center, Phoenix
Mayo Clinic Arizona, Phoenix
Mercy General Hospital, Sacramento
Sunnybrook Health Sciences Center, Toronto
St. Michael's Hospital, Toronto
The Montreal Heart Institute, Montreal
CHUM Hotel Dieu, Montreal
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Milestone Pharmaceuticals Inc.
OTHER